Fig. 3From: Computational approach towards the design of artemisinin–thymoquinone hybrids against main protease of SARS-COV-2Drug interaction sites used as control ligands identified by molecular docking. In the figure, Mpro SARS-COV-2 is presented docked with A N3 inhibitor; B chloroquine, C control ligands; D anakinra, E azithromycin, F baricitinib e G remdesivirBack to article page